A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Latest Information Update: 29 Aug 2024
At a glance
- Drugs Telisotuzumab vedotin (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms TeliMET NSCLC-01
- Sponsors AbbVie
- 15 Aug 2024 Planned primary completion date changed from 7 Jun 2025 to 21 Mar 2028.
- 04 Jun 2024 Design,presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 30 Apr 2024 Planned End Date changed from 3 Jul 2026 to 21 Mar 2028.